PTCT Q2 2022 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$166M+41.9% YoY

Gross Profit

$156M94.2% margin

Operating Income

-$92M-55.8% margin

Net Income

-$152M-91.9% margin

EPS (Diluted)

$-2.13

QoQ Revenue Growth

+11.3%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$73M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.0B

Stockholders' Equity

-$182M

Cash & Equivalents

$158M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$166M	$117M	+41.9%
Gross Profit	$156M	$109M	+42.6%
Operating Income	-$92M	-$98M	+6.2%
Net Income	-$152M	-$118M	-28.5%

Geographic Segments

Non-US

$77M58%

United States

$57M42%